Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Mercury Biopharmaceutical's Enterprise Value is NT$2,351.35 Mil.
Mercury Biopharmaceutical's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-66.27 Mil. Therefore, Mercury Biopharmaceutical's EV-to-EBIT ratio for today is -35.48.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Mercury Biopharmaceutical (ROCO:6932) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Mercury Biopharmaceutical's EV-to-EBIT for today is
Mercury Biopharmaceutical's current Enterprise Value is NT$2,351.35 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Mercury Biopharmaceutical's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-66.27 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Mercury Biopharmaceutical's EV-to-EBITDA for today is:
Mercury Biopharmaceutical's current Enterprise Value is NT$2,351.35 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Mercury Biopharmaceutical's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-54.64 Mil.
Mercury Biopharmaceutical's current Enterprise Value is NT$2,351.35 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Mercury Biopharmaceutical's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.00 Mil.
Mercury Biopharmaceutical's current Enterprise Value is NT$2,351.35 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Mercury Biopharmaceutical's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-50.84 Mil.
Mercury Biopharmaceutical's current Enterprise Value is NT$2,351.35 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Mercury Biopharmaceutical's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-58.14 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mercury Biopharmaceutical Enterprise Value Related Terms
Mercury Biopharmaceutical Enterprise Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6932 vs ZTS, UTHR: Enterprise Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Mercury Biopharmaceutical's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mercury Biopharmaceutical Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mercury Biopharmaceutical's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Mercury Biopharmaceutical's Enterprise Value falls into.
Mercury Biopharmaceutical Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Mercury Biopharmaceutical's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of NT$2,351.35 Mil mean?
Mercury Biopharmaceutical (ROCO:6932) has a Enterprise Value of NT$2,351.35 Mil as of Jul. 14, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Mercury Biopharmaceutical and its competitors.
Is Mercury Biopharmaceutical's Enterprise Value too high?
Mercury Biopharmaceutical's current Enterprise Value is NT$2,351.35 Mil. Overall, Mercury Biopharmaceutical has a GF Score™ of 25/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mercury Biopharmaceutical's Enterprise Value compare to ZTS and UTHR?
Mercury Biopharmaceutical's Enterprise Value of NT$2,351.35 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Mercury Biopharmaceutical and its competitors. Mercury Biopharmaceutical's current Enterprise Value is NT$2,351.35 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mercury Biopharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Mercury Biopharmaceutical (ROCO:6932) is currently considered Possible Value Trap. The stock's GF Value™ is NT$36.00, compared to a current price of NT$5.93 — trading 83.5% below its estimated fair value. The current Enterprise Value is NT$2,351.35 Mil. Mercury Biopharmaceutical's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Mercury Biopharmaceutical (ROCO:6932), the current Enterprise Value is NT$2,351.35 Mil as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mercury Biopharmaceutical (ROCO:6932) Overvalued in 2026?
Based on GuruFocus' analysis, Mercury Biopharmaceutical stock appears to be undervalued.
The current stock price of NT$5.93 is trading 83.5% below its estimated GF Value™ of NT$36.00.
GuruFocus considers Mercury Biopharmaceutical to be Possible Value Trap.
Key valuation signals for ROCO:6932:
Enterprise Value: NT$2,351.35 Mil
GF Value™: NT$36.00 vs. price of NT$5.93 (83.5% below fair value)
No single metric tells the full story. See the ROCO:6932 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mercury Biopharmaceutical Corp focuses on the development of drugs for unmet medical needs. It offers a development platform focusing on rapid release and free adjustable doses. Its 3D powder bonding method (binder jetting) combines powder and special molding adhesive and stacks them in layers.
25GF Score
Get the complete analysis for ROCO:6932
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6932 has been successfully added to your 
